Lysoway Therapeutics, Inc., a biotechnology company advancing structure-guided small-molecule modulators of lysosomal ion channels to treat age-related neurodegeneration, today announced that its lead ...

CARMEL, Ind.--(BUSINESS WIRE)--Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, announced today ...

The Classic WD-40 ® Product is a versatile solution that protects metal from rust and corrosion, displaces moisture, and lubricates almost anything. But when you need to cut through deep rust and ...

Sanofi will gain exclusivity rights to Ventyx Biosciences’ CNS-penetrant candidate VTX3232 as part of a $27m deal. Under the terms of the agreement, Sanofi will buy 70,601 shares of Ventyx’s Series A ...

NEW YORK, Dec. 10, 2025 /PRNewswire/ -- Formation Bio and Lynk Pharmaceuticals today announced Formation Bio's acquisition of worldwide rights, excluding Greater China, to LNK01006, a next generation ...

We recently compiled a list of 11 Best Future Stocks to Buy Now. Denali Therapeutics Inc. stands sixth on our list among the best future stocks. Denali Therapeutics Inc. (NASDAQ:DNLI) is a ...

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a ...

First safety-and-efficacy readout from selective PARP1 inhibitor EIK1003-001 New clinical trial collaboration and supply agreement with Merck First patient dosed in Phase 1/2 study of CNS-penetrant ...

During manufacture and assembly of products, there is a wide range of testing and inspection carried out to ensure the materials and items satisfy their specifications or are fit for the required ...

Lysoway Therapeutics, Inc., a biotechnology company advancing structure-guided small-molecule modulators of lysosomal ion channels to treat age-related neurodegeneration, today announced that its lead ...